Katherine Szarama
Coverage of Katherine Szarama in the Nexus archive.
- Opinion: STAT+: Dark times ahead at the FDA
FDA Commissioner Marty Makary was ousted along with Tracy Beth Høeg (CDER leader) and Katherine Szarama (CBER acting director), leaving three crucial FDA positions with only acting leadership. The simultaneous removal of these three high-ranking officials is characterized as an unprecedented ideological purge that has created significant instability within the agency.
- Second FDA executive departing organization in less than a week as top drug regulator claims she was fired
Dr. Tracy Beth Høeg, former acting director of the FDA's Center for Drug Evaluation and Research, claimed she was fired, becoming the second high-ranking official to depart the FDA this week. Her departure follows that of former FDA Commissioner Dr. Marty Makary. Høeg will be replaced by her former deputy, Dr. Mike Davis.
- FDA turmoil deepens as top drug chief departs claiming she was fired
The FDA is experiencing turmoil as top regulators, including Dr. Tracy Beth Høeg and Katherine Szarama, have left their positions, with Høeg claiming she was fired. The agency now lacks permanent leaders in key roles. This shake-up follows the resignation of Marty Makary.
- FDA names new director for vaccines, biologics unit
The FDA has appointed Katherine Szarama as the acting director of its vaccines and biologics unit, replacing Vinay Prasad. A Department of Health and Human Services official confirmed the change to The Hill.